Entering text into the input field will update the search result below

Matinas Bio beats Q2 consensus

  • Matinas Biopharma (MTNB) Q2 results: Revenues: $0.09M (unch).
  • Net loss: ($3.6M) (-0.8%); loss/share: ($0.03) (+25.0%); Quick Assets: $36.8M (+196.8%).
  • The Company is on track to initiate an additional head-to-head comparative study of MAT9001 and Vascepa in Q1 2020.
  • NIH-funded Phase 1/2 EnACT trial of MAT2203 in cryptococcal meningitis to commence in Q4 2019. Cumulative data is expected in H1 2021.
  • Previously: Matinas Biopharma Holdings EPS beats by $0.01, beats on revenue (Aug. 13)

Recommended For You

More Trending News

About MTNB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MTNB--
Matinas BioPharma Holdings, Inc.